Incredibly Popular Peptide Regrew 'Irreplaceable' Cartilage
A solo explainer on how a lizard-venom peptide led to semaglutide, and on a small study Stanfield says suggests it may affect knee cartilage independently of weight loss.
Key moments
Tap a moment to play the video from there.
- 0:00Gila monster venom and John EngStanfield introduces Eng, who ordered dried venom in the early 1990s and noticed something others missed. He sets up the story of a drug class that kept producing surprises.
- 1:31Exendin-4 and the GLP-1 linkStanfield says Eng found exendin-4 in 1992, 53% identical to human GLP-1 and far longer lasting. He says that raised the prospect of a once-injected diabetes drug.
- 3:01Byetta approval and its successorsHe describes the path from Amylin's license to Byetta in 2005, then liraglutide and weekly semaglutide. He calls Byetta modest, with about 5% weight loss.
- 4:01Unexpected effects beyond blood sugarStanfield covers weight loss, cardiovascular outcomes in SELECT, lower addiction rates in a VA study, and kidney results in FLOW. He ties these to GLP-1 receptors found in many tissues.
- 6:05The 283-year cartilage doctrineHe recounts William Hunter's 1743 statement and explains that cartilage lacks blood supply and nerves, so repair is limited. He says current treatments fall short for many.
- 7:07STEP 9 and the weight-loss explanationStanfield reports STEP 9 in 407 people, with pain scores down 42 points on semaglutide versus 28 on placebo. He says most assumed weight loss explained it.
- 8:08The pair-fed preclinical experimentHe describes Chen's team matching weight loss without the drug. He says only the semaglutide group preserved cartilage, with less inflammation and fewer bone spurs.
- 9:08Proposed energy mechanismStanfield explains, using a generator analogy, that cartilage cells run on an inefficient fuel source. He says GLP-1 receptor activation shifts them to oxidative phosphorylation via AMPK and PFKFB3.
- 10:09The 20-patient pilot studyHe describes patients aged 50 to 75 given hyaluronic acid with or without weekly semaglutide for 24 weeks. He reports a 17% MRI increase in cartilage thickness versus under 1%.
- 10:39Limitations and exercise teaserStanfield stresses the small size and short duration and quotes the authors' call for caution. He then points viewers to a follow-up video on exercise for knee arthritis.
What the video says
Brad Stanfield opens with the history of GLP-1 drugs and ends on a recent semaglutide study in knee osteoarthritis. He tells how endocrinologist John Eng found exendin-4 in Gila monster venom in 1992. Stanfield says it is 53% identical to human GLP-1 but lasted hours in preclinical studies, while natural GLP-1 breaks down within about 2 minutes. He says Eng paid for the patent himself, drug companies passed on it for three years, and Amylin licensed it in 1996, leading to the FDA approval of Byetta in April 2005.
Stanfield then follows the later drugs: liraglutide in 2010, weekly semaglutide in 2017, and semaglutide's approval for obesity in 2021. He describes a run of effects he calls unexpected. These include weight loss of around 15%, a 20% reduction in major cardiovascular events in the SELECT trial, lower rates of substance-use problems in a VA study (18% for alcohol, 20% for nicotine, 25% for opioids), and kidney benefits in the FLOW trial. He says GLP-1 receptors turn up in the brain, heart and kidneys, not just the gut and pancreas.
The main section is about cartilage. Stanfield recounts a 1743 claim that damaged cartilage is never recovered and explains why it repairs poorly. He says the STEP 9 trial in 407 people with knee arthritis looked like a weight-loss story. He then describes a preclinical experiment by Dai Chen's group in Shenzhen in which calorie-restricted animals lost as much weight as the semaglutide group, yet only the semaglutide group kept its cartilage. He relays a proposed mechanism in which GLP-1 receptors on cartilage cells shift them toward more efficient energy production. He also reports a 20-patient pilot study in which MRI showed a 17% increase in cartilage thickness with semaglutide, against under 1% in the control group.
Stanfield is explicit about the limits: the pilot was small and lasted 24 weeks, and the authors urged caution. He closes by pointing to a follow-up video on exercise for knee arthritis.
On each compound
Semaglutide4:01
Stanfield describes semaglutide's reported effects beyond blood sugar, including weight loss, fewer cardiovascular events in SELECT, and kidney benefits in FLOW. He says patients on it lost about 15% of body weight.
See how your DNA reads SemaglutideSemaglutide8:08
Stanfield says a preclinical experiment by Dai Chen's group found cartilage was preserved with semaglutide but not with matched weight loss alone. He says a 20-patient pilot reported a 17% increase in cartilage thickness on MRI.
See how your DNA reads Semaglutide“When destroyed, it is never recovered.”
What this video doesn’t settle
- The human evidence is a pilot of 20 patients over 24 weeks, and Stanfield himself says much larger and longer trials are needed.
- The weight-independence finding comes from a preclinical experiment, and Stanfield acknowledges that those results may not carry over to human cartilage.
- The energy-pathway explanation is described as a proposed mechanism, and the video does not show it being confirmed in people.
Questions this video answers
Does semaglutide help knee cartilage independently of weight loss?
Stanfield says a preclinical experiment from Dai Chen's team at the Shenzhen Institutes of Advanced Technology compared semaglutide with calorie restriction giving equal weight loss. Only the semaglutide group kept its cartilage, which he takes to mean a mechanism independent of weight. He adds that this is early evidence.
What did the semaglutide knee osteoarthritis pilot study find?
According to Stanfield, 20 patients aged 50 to 75 with obesity and knee arthritis received hyaluronic acid with or without weekly semaglutide for 24 weeks. MRI showed an average 17% increase in cartilage thickness in the semaglutide group versus under 1% in controls. He also reports less pain and better joint function.
Where did GLP-1 drugs like Ozempic come from?
Stanfield traces them to John Eng's 1992 discovery of exendin-4 in Gila monster venom. It led to Byetta in 2005, then liraglutide in 2010 and semaglutide in 2017. He says each generation was more potent and longer lasting.
How might semaglutide act on cartilage cells, according to this video?
Stanfield says GLP-1 receptors on cartilage cells activate an AMPK and PFKFB3 signaling cascade. He says this shifts the cells from glycolysis to oxidative phosphorylation, giving them more energy for tissue repair. He presents this as the proposed explanation, not a settled one.
Video by Dr Brad Stanfield on YouTube, embedded as published. The summary is written by PeptidesDNA from the video; every claim in it is the speaker’s. Not affiliated with or endorsed by the creator. Not medical advice.
